49.94

4.81% 2.29

After Hours: 50.36 0.42 +0.84%

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $49.94, with a volume of 3.24M. It is up +4.81% in the last 24 hours and up +63.52% over the past month. Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$47.65

Open:

$48.97

24h Volume:

3.24M

Relative Volume:

1.59

Market Cap:

$6.17B

Revenue:

$692.26M

Net Income/Loss:

$-512.41M

P/E Ratio:

-11.78

EPS:

-4.24

Net Cash Flow:

$-274.36M

1W Performance:

+2.76%

1M Performance:

+63.52%

6M Performance:

+37.61%

1Y Performance:

+124.35%

1-Day Range:

$48.32

$50.89

1-Week Range:

$45.59

$50.89

52-Week Range:

$15.81

$50.89

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1174)

Industry

Diagnostics & Research (59)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

1,779

Twitter

@guardanthealth

Next Earnings Date

2024-11-06

Latest SEC Filings

GH's Discussions on Twitter

Compare GH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GH Guardant Health Inc	49.94	6.17B	692.26M	-512.41M	-274.36M	-4.24
TMO Thermo Fisher Scientific Inc	606.74	232.08B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	223.08	160.42B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	151.38	42.01B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	201.78	36.62B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	423.99	34.72B	3.84B	866.24M	792.60M	10.37

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-25	Initiated	Barclays	Overweight
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

04:05 AM

Guardant Health Q4 Earnings: A Critical Moment for Precision Oncology Leaders - StockTitan

04:05 AM

10:46 AM

Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program - Marketscreener.com

10:46 AM

10:03 AM

Guardant Health stock soars to 52-week high of $49.97 - Investing.com

10:03 AM

08:05 AM

Guardant Health Secures Landmark Deal: 10,000 Cancer Screenings Set for Abu Dhabi - StockTitan

08:05 AM

03:56 AM

Exchange Traded Concepts LLC Decreases Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

03:56 AM

03:54 AM

Guardant Health, Inc. (NASDAQ:GH) Shares Sold by SG Americas Securities LLC - MarketBeat

03:54 AM

Jan 29, 2025

The Goldman Sachs Group Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price - MarketBeat

Jan 29, 2025

Jan 28, 2025

Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat

Jan 28, 2025

Jan 26, 2025

Okla And Rigetti Computing Are Among Top 8 Mid Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? - Benzinga

Jan 26, 2025

Barclays Initiates Coverage of Guardant Health (GH) with Overweight Recommendation - MSN

Jan 24, 2025

Leerink Partnrs Weighs in on Guardant Health Q4 Earnings - Defense World

Jan 24, 2025

Jan 23, 2025

Barclays initiates Guardant Health stock with Overweight rating By Investing.com - Investing.com Canada

Jan 23, 2025

Guardant Reveal aids organ preservation in rectal cancer treatment - Investing.com India

Jan 23, 2025

Barclays Begins Coverage on Guardant Health (NASDAQ:GH) - MarketBeat

Jan 23, 2025

Barclays initiates Guardant Health stock with Overweight rating - Investing.com

Jan 23, 2025

Q4 EPS Estimate for Guardant Health Increased by Analyst - MarketBeat

Jan 23, 2025

Guardant Health to Present Major Cancer Detection Breakthroughs at ASCO GI 2025 Symposium - StockTitan

Jan 23, 2025

Jan 22, 2025

Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week - MSN

Jan 22, 2025

Guardant Health (NASDAQ:GH) Shares Up 6.4%Here's Why - MarketBeat

Jan 22, 2025

Guardant Health's (GH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat

Jan 22, 2025

Guardant Health stock hits 52-week high of $39.61 amid growth - Investing.com Australia

Jan 22, 2025

Wealthcare Advisory Partners LLC Takes $252,000 Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

Jan 22, 2025

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 43% Share Price Bounce - Simply Wall St

Jan 22, 2025

Jan 21, 2025

Guardant stock jumps 12% on Medicare coverage expansion - MSN

Jan 21, 2025

Guardant Health director Tariq Musa sells shares worth $4,359 - MSN

Jan 21, 2025

Raymond James maintains Outperform on Guardant Health, $39 target - MSN

Jan 21, 2025

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone - MSN

Jan 21, 2025

Why This Top 4% Cancer-Tied Stock Just Hit A 13-Month High - Investor's Business Daily

Jan 21, 2025

Canaccord maintains Guardant Health stock Buy rating and $42 target - MSN

Jan 21, 2025

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test - Yahoo Finance

Jan 21, 2025

Guardant Health (NASDAQ:GH) Reaches New 52-Week HighShould You Buy? - MarketBeat

Jan 21, 2025

Guardant Health Stocks Surge on Medicare Boost - TipRanks

Jan 21, 2025

Guardant Health shares climb on expanded Medicare coverage for colon cancer test - Investing.com Canada

Jan 21, 2025

Guardant Health: Remains Risky Despite SHIELD’s Early Success (NASDAQ:GH) - Seeking Alpha

Jan 21, 2025

Guardant Health, Inc. Receives Medicare Coverage for Guardant Reveal on Smart Liquid Biopsy?? Platform for Surveillance Testing in Colorectal Cancer Patients - Marketscreener.com

Jan 21, 2025

Jan 20, 2025